Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
43.60
+3.02 (7.44%)
Jan 21, 2025, 4:00 PM EST - Market closed
Veracyte Employees
Veracyte had 815 employees as of December 31, 2023. The number of employees increased by 28 or 3.56% compared to the previous year.
Employees
815
Change (1Y)
28
Growth (1Y)
3.56%
Revenue / Employee
$521,879
Profits / Employee
-$11,372
Market Cap
3.38B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
VCYT News
- 6 weeks ago - Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines - Business Wire
- 2 months ago - Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veracyte Announces Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 - Business Wire
- 4 months ago - New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer - Business Wire
- 4 months ago - Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors - Business Wire
- 5 months ago - Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire